NCT06705530View on ClinicalTrials.gov

A Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Patients with B-cell Lymphoproliferative Disorders

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

November 26, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

March 31, 2026

Conditions
Non-Hodgkin Lymphoma, B-cellAcute Lymphoblastic Leukemia ALL
Interventions
BIOLOGICAL

Hem101

CAR-T lymphocytes specific to CD19 B-cell antigen

Trial Locations (1)

125167

RECRUITING

National Medical Research Center for Hematology, Moscow

All Listed Sponsors
lead

National Research Center for Hematology, Russia

NETWORK